Program
treprostinil
Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeutics | 625 open or running | phase 4since Apr 14, 2003 | Oct 18, 1999 | Nov 2027phase 3 · NCT05943535 |
| Liquidia Technologies | 64 open or running | phase 4since Aug 7, 2026 | Jan 3, 2018 | Feb 2027phase 2 · NCT07748000 |
| Mannkind | 10 open or running | phase 1since Mar 1, 2018 | Mar 1, 2018 | none ahead |
| Pharmosa Biopharm | 10 open or running | phase 1since Jul 23, 2019 | Jul 23, 2019 | none ahead |
| SciPharm SàRL | 10 open or running | phase 3since Aug 12, 2011 | Aug 12, 2011 | none ahead |
Also a collaborator on its studies: ppd-development-lp, nuventra-inc, fgk-clinical-research-gmbh and cvie-therapeutics-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Mar 20, 2008.
- Mar 4, 2019Phase 2 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT03884465 · 15 enrolled · France, Germany
- May 9, 2019Phase 1 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT03950739 · 51 enrolled · United States
- Jun 5, 2019Phase 3 study in Familial Primary Pulmonary HypertensionLiquidia Technologies · NCT03992755 · 92 enrolled · United States
- Jul 23, 2019Pharmosa Biopharm's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Pharmosa BiopharmPharmosa Biopharm · NCT04041648 · 52 enrolled · United States
- Jan 12, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04708782 · 598 enrolled · United States, Canada, Chile
- May 20, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04905693 · 1,850 planned · United States, Argentina, Australia and more
- Jan 10, 2022Phase 4 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT05203510 · 52 enrolled · United States
- Feb 15, 2022Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT05255991 · 597 enrolled · Argentina, Australia, Belgium and more
- Jul 5, 2023Phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535 · 698 planned · United States, Argentina, Australia and more
- Dec 11, 2025Phase 3 study in Hypertension, PulmonaryLiquidia Technologies · NCT07285655 · 344 planned · United States, Australia, Austria and more
- Jul 31, 2026Phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000 · 75 planned
- Aug 7, 2026Phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804 · 20 planned · United States
- Oct 19, 2026Phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591 · 40 planned · United States
- Oct 19, 2026Phase 3 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923526 · 400 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000
- May 2027Primary completion: phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804
- Nov 2027Primary completion: phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535
- May 2028Primary completion: phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591
TargetBeta
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selexipagrule | Johnson & Johnson | phase 4 | 23 |
Studies
The newest 60 of 71 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07923591Hypertension, Pulmonary · United States | 2 | Not yet recruiting | United Therapeutics | May 2028 | 40 |
| NCT07923526Hypertension, Pulmonary · United States | 3 | Not yet recruiting | United Therapeutics | Sep 2034 | 400 |
| NCT07759804Pulmonary Arterial Hypertension · United States | 4 | Recruiting | Liquidia Technologies | May 2027 | 20 |
| NCT07748000Scleroderma, Systemic | 2 | Not yet recruiting | Liquidia Technologies | Feb 2027 | 75 |
| NCT07285655Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Recruiting | Liquidia Technologies | Jul 2029 | 344 |
| NCT05943535Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | United Therapeutics | Nov 2027 | 698 |
| NCT05255991Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more | 3 | Completed | United Therapeutics | Jun 30, 2025 | 597 |
| NCT05203510Pulmonary Arterial Hypertension · United States | 4 | Active, not recruiting | United Therapeutics | Apr 30, 2026 | 52 |
| NCT04905693Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | By invitation | United Therapeutics | Dec 2029 | 1,850 |
| NCT04708782Idiopathic Pulmonary Fibrosis · United States, Canada, Chile | 3 | Completed | United Therapeutics | Feb 2, 2026 | 598 |
| NCT04041648Pulmonary Arterial Hypertension · United States | 1 | Completed | Pharmosa Biopharm | Sep 20, 2019 | 52 |
| NCT03992755Familial Primary Pulmonary Hypertension · United States | 3 | Active, not recruiting | Liquidia Technologies | May 31, 2025 | 92 |
| NCT03950739Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 22, 2023 | 51 |
| NCT03884465Pulmonary Arterial Hypertension · France, Germany | 2 | Terminated | Liquidia Technologies | Dec 23, 2020 | 15 |
| NCT03794583Hypertension, Pulmonary · United States, Israel, Italy | 3 | Terminated | United Therapeutics | Nov 29, 2022 | 41 |
| NCT03496623Hypertension, Pulmonary · United States, Argentina, Israel and more | 3 | Terminated | United Therapeutics | Oct 13, 2022 | 188 |
| NCT03497689Pulmonary Arterial Hypertension · United States | 4 | Completed | United Therapeutics | May 11, 2022 | 36 |
| NCT03464864Pulmonary Arterial Hypertension · United States | 1 | Completed | Mannkind | Jun 5, 2018 | 36 |
| NCT03399604Familial Primary Pulmonary Hypertension · United States | 3 | Completed | Liquidia Technologies | May 6, 2019 | 121 |
| NCT03055221Pulmonary Arterial Hypertension | 4 | Completed | United Therapeutics | Feb 25, 2014 | 20 |
| NCT03043651Hypertension, Pulmonary · United States | 3 | Terminated | United Therapeutics | Mar 2, 2020 | 48 |
| NCT03055234Pulmonary Hypertension Associated With Sickle Cell Disease | 3 | Withdrawn | United Therapeutics | Dec 2021 | 0 |
| NCT03037580Hypertension, Pulmonary · United States | 3 | Terminated | United Therapeutics | Dec 3, 2019 | 84 |
| NCT03016468Pulmonary Arterial Hypertension | 2 | Withdrawn | United Therapeutics | Sep 2018 | 0 |
| NCT03012646Hypertension, Pulmonary | 2 | Withdrawn | United Therapeutics | Apr 2019 | 0 |
| NCT02999906Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2021 | 0 |
| NCT02893995Pulmonary Arterial Hypertension · China | 4 | Withdrawn | United Therapeutics | Apr 2018 | 0 |
| NCT02882126Pulmonary Arterial Hypertension · China | 4 | Withdrawn | United Therapeutics | Jun 2021 | 0 |
| NCT02847260Pulmonary Arterial Hypertension | 4 | Completed | United Therapeutics | Mar 2014 | 39 |
| NCT02633293Hypertension, Pulmonary · United States, Puerto Rico | 3 | Terminated | United Therapeutics | Aug 1, 2021 | 243 |
| NCT02630316Hypertension, Pulmonary · United States, Puerto Rico | 3 | Completed | United Therapeutics | Dec 26, 2019 | 326 |
| NCT02603068Hypertension, Pulmonary · United States | 2 | Withdrawn | United Therapeutics | Apr 2018 | 0 |
| NCT02276872PAH · United States | 2 | Completed | United Therapeutics | Jul 20, 2017 | 32 |
| NCT02318758Healthy · United States | 1 | Completed | United Therapeutics | Oct 2014 | 32 |
| NCT02261883Persistent Fetal Circulation Syndrome · United States | 2 | Terminated | United Therapeutics | Sep 27, 2022 | 42 |
| NCT01934582Pulmonary Arterial Hypertension · United States | 3 | Completed | United Therapeutics | Nov 2013 | 13 |
| NCT01884038Reperfusion Injury · United States | 3 | Withdrawn | United Therapeutics | Jun 2010 | 0 |
| NCT01746485Healthy · United States | 1 | Completed | United Therapeutics | Jul 2012 | 19 |
| NCT01557660Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2018 | 0 |
| NCT01557647Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2015 | 0 |
| NCT01560637Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | United Therapeutics | Aug 12, 2021 | 471 |
| NCT01560624Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | United Therapeutics | Jun 24, 2018 | 690 |
| NCT01588405Pulmonary Arterial Hypertension · United States | 2 | Completed | United Therapeutics | Jul 2014 | 33 |
| NCT01477333Pulmonary Arterial Hypertension · United States | 2 | Completed | United Therapeutics | Nov 2013 | 18 |
| NCT01416636Non-operable Chronic Thromboembolic Pulmonary Hypertension · Austria, Czechia, Germany and more | 3 | Completed | SciPharm SàRL | Nov 2016 | 105 |
| NCT01172496Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 24 |
| NCT01165476Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 64 |
| NCT01153386Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 36 |
| NCT01131845Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Sep 2010 | 16 |
| NCT01104870Hypertension, Pulmonary · United States | 2 | Completed | United Therapeutics | Jan 2013 | 50 |
| NCT01027949Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 3 | Completed | United Therapeutics | Feb 12, 2020 | 894 |
| NCT00963027Hypertension, Pulmonary · United States | 1 | Completed | United Therapeutics | Oct 2009 | 30 |
| NCT00963001Hypertension, Pulmonary · United States | 1 | Completed | United Therapeutics | Nov 2009 | 32 |
| NCT00887978Hypertension, Pulmonary · United States, Belgium, Canada and more | 3 | Completed | United Therapeutics | Jul 2011 | 310 |
| NCT00848939Scleroderma, Systemic · United States | 1 | Completed | United Therapeutics | Jan 2010 | 28 |
| NCT00848107Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Terminated | United Therapeutics | Sep 2011 | 115 |
| NCT00775463Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Completed | United Therapeutics | Mar 2011 | 148 |
| NCT00760916Hypertension, Pulmonary · United States, Australia, Mexico | 3 | Withdrawn | United Therapeutics | Jan 2009 | 0 |
| NCT00741819Pulmonary Arterial Hypertension · United States | 4 | Completed | United Therapeutics | Mar 2010 | 73 |
| NCT00643604Hypertension, Pulmonary · United States | 4 | Terminated | United Therapeutics | Jan 2010 | 7 |
How it is read
Names in the registry
- “Inhaled Treprostinil”, 7 entries
- “treprostinil diethanolamine”, 6 entries
- “Oral Treprostinil”, 5 entries
- “treprostinil sodium”, 5 entries
- “UT-15C SR”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 38 studies
- Hypertension, Pulmonary, 17 studies
- Scleroderma, Systemic, 4 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Chronic Limb-Threatening Ischemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.